F-star Therapeutics Inc

NASDAQ:FSTX  
7.20
-1.67 (-18.83%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)52.67M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.83 Million
Adjusted EPS-$1.39
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

F-star Therapeutics Inc Stock, NASDAQ:FSTX

Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT
United States of America
Phone: +44.1223.497.400
Number of Employees: 75

Description

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company is headquartered in Cambridge, the United Kingdom.